Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands

Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands

© 2013 by Lippincott Williams & Wilkins. Background: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) as part of combination antiretroviral therapy. Dosing is based on body weight...

Saved in:

書目詳細資料
Main Authors:	Diane E.T. Bastiaans, Silvia Forcat, Hermione Lyall, Tim R. Cressey, Rawiwan Hansudewechakul, Suparat Kanjanavanit, Antoni Noguera-Julian, Christoph Konigs, Jamie R.J. Inshaw, Suwalai Chalermpantmetagul, Yacine Saidi, Alexandra Compagnucci, Lynda M. Harper, Carlo Giaquinto, Angela P.H. Colbers, David M. Burger
格式:	雜誌
出版:	2018
在線閱讀:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84890378736&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/45156
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!
機構:	Chiang Mai University

相似書籍

Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands
由: Diane E.T. Bastiaans, et al.
出版: (2018)

Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: Comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
由: Kulkanya Chokephaibulkit, et al.
出版: (2018)

Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: Comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
由: Chokephaibulkit K., et al.
出版: (2014)

Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: Comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
由: Kulkanya Chokephaibulkit, et al.
出版: (2018)

CRYSTALLOGRAPHIC STUDY ON DRUGS MIXTURE OF LOPINAVIR AND RITONAVIR
由: Budi Setianto, Arif

Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy
由: Tim R. Cressey, et al.
出版: (2018)

Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy
由: Tim R. Cressey, et al.
出版: (2018)

A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: The HIV STAR study
由: Torsak Bunupuradah, et al.
出版: (2018)

Pharmacokinetic interactions between quinine and lopinavir/ritonavir in healthy Thai adults
由: Siwalee Rattanapunya, et al.
出版: (2018)

Pharmacokinetic interactions between quinine and lopinavir/ritonavir in healthy Thai adults
由: Siwalee Rattanapunya, et al.
出版: (2018)

Chemometrics-assisted UV spectrophotometric method for determination of lopinavir and ritonavir in syrup
由: Chutima Matayatsuk Phechkrajang, et al.
出版: (2018)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
由: Siwalee Rattanapunya, et al.
出版: (2018)

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
由: Cressey T., et al.
出版: (2017)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
由: Siwalee Rattanapunya, et al.
出版: (2018)

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
由: Tim R. Cressey, et al.
出版: (2018)

Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers
由: Polina German, et al.
出版: (2018)

Pharmacokinetics of low-dose lopinavir/ritonavir tablet formulation in HIV-1 infected children
由: Thanyawee Puthanakit, et al.
出版: (2010)

Twice Blessed, by Rosca
由: Burns, Gerald T.
出版: (2012)

Twice Blessed, by Rosca
由: Reyes, Danilo Francisco
出版: (2012)

The Rites of the twice-born
由: Stevenson, Sinclair, Mrs.
出版: (1920)

A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
由: Purwati, Purwati, et al.
出版: (2021)

A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
由: Purwati, -, et al.
出版: (2021)

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
由: Pauline Byakika-Kibwika, et al.
出版: (2018)

Erratum: A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: The HIV STAR study (Antiviral Therapy (2012) DOI: 10.3851/IMP2443)
由: Torsak Bunupuradah, et al.
出版: (2018)

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings
由: John A. Bartlett, et al.
出版: (2018)

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings
由: Bartlett J., et al.
出版: (2017)

Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone
由: Satriyo Dwi Suryantoro, -, et al.
出版: (2021)

Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults
由: Tim R. Cressey, et al.
出版: (2018)

Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults
由: Tim R. Cressey, et al.
出版: (2018)

Insulin resistance and lipid profiles in HIVinfected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy
由: Prapai Dejkhamron, et al.
出版: (2018)

Insulin resistance and lipid profiles in HIVinfected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy
由: Dejkhamron P., et al.
出版: (2014)

A phase II/III trial of lopinavir/ritonavir dosed according to the WHO pediatric weight band dosing guidelines
由: Jorge A. Pinto, et al.
出版: (2018)

Insulin resistance and lipid profiles in HIVinfected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy
由: Prapai Dejkhamron, et al.
出版: (2018)

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial
由: C. Orkin, et al.
出版: (2018)

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial
由: C. Orkin, et al.
出版: (2018)

You never step in the same river twice.
由: Choo, Yan Bing.
出版: (2011)

Twicing local linear kernel regression smoothers
由: Zhang, W., et al.
出版: (2014)

Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy
由: Patumrat Sripan, et al.
出版: (2018)

Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy
由: Sripan P., et al.
出版: (2017)

Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series
由: Manoon Surabotsophon, et al.
出版: (2020)